Trial Profile
Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Metadoxine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Alcobra
- 06 Aug 2013 A secondary analysis of this trial was published in Postgraduate Medicine Journal, according to an Alcobra media release.
- 17 Oct 2012 Results presented at the 25th Annual Congress of the European College of Neuropsychopharmacology.
- 17 Apr 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.